sinemet 10 mg/100 mg tablets
merck sharp & dohme ireland (human health) limited - carbidopa; levodopa - tablet - 10 mg/100 milligram(s) - dopa and dopa derivatives; levodopa and decarboxylase inhibitor
sinemet 25 mg/250 mg tablets
merck sharp & dohme ireland (human health) limited - levodopa; carbidopa - tablet - 25 mg/250 milligram(s) - dopa and dopa derivatives; levodopa and decarboxylase inhibitor
sinemet 12.5 mg/50 mg tablets
merck sharp & dohme ireland (human health) limited - carbidopa; levodopa - tablet - 12.5 mg/50 milligram(s) - dopa and dopa derivatives; levodopa and decarboxylase inhibitor
sinemet plus 25 mg/100 mg tablets
merck sharp & dohme ireland (human health) limited - levodopa; carbidopa - tablet - 25 mg/100 milligram(s) - dopa and dopa derivatives; levodopa and decarboxylase inhibitor
carbidopa/levodopa fair-med 12.5mg/50mg tablets
fairmed healthcare gmbh - levodopa; carbidopa - tablet - 12.5/50 milligram(s) - dopa and dopa derivatives; levodopa and decarboxylase inhibitor
carbidopa/levodopa fair-med 10 mg/100 mg tablets
fairmed healthcare gmbh - carbidopa; levodopa - tablet - 10/100 milligram(s) - dopa and dopa derivatives; levodopa and decarboxylase inhibitor
carbidopa/levodopa fair-med 25 mg/100 mg tablets
fairmed healthcare gmbh - carbidopa; levodopa - tablet - 25/100 milligram(s) - dopa and dopa derivatives; levodopa and decarboxylase inhibitor
carbidopa/levodopa fair-med 25 mg/250 mg tablets
fairmed healthcare gmbh - carbidopa; levodopa - tablet - 25/250 milligram(s) - dopa and dopa derivatives; levodopa and decarboxylase inhibitor
levodopa/carbidopa/entacapone orion
orion corporation - levodopa, carbidopa, entacapone - parkinson disease - nervous system - levodopa/carbidopa/entacapone orion is indicated for the treatment of adult patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa / dopa-decarboxylase (ddc)-inhibitor treatment.
stalevo
orion corporation - levodopa, carbidopa, entacapone - parkinson disease - anti-parkinson drugs - stalevo is indicated for the treatment of adult patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa / dopa-decarboxylase (ddc)-inhibitor treatment.